Cargando…

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer

Prostate cancer (PCa) is the second leading cause of cancer death for men in the United States. While organ-confined disease has reasonable expectation of cure, metastatic PCa is universally fatal upon recurrence during hormone therapy, a stage termed castration-resistant prostate cancer (CRPC). Unt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gordon, Nicolas, Gallagher, Peter T., Neupane, Neermala Poudel, Mandigo, Amy C., McCann, Jennifer K., Dylgjeri, Emanuela, Vasilevskaya, Irina, McNair, Christopher, Paller, Channing J., Kelly, Wm. Kevin, Knudsen, Karen E., Shafi, Ayesha A., Schiewer, Matthew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055378/ https://www.ncbi.nlm.nih.gov/pubmed/36993449 http://dx.doi.org/10.1101/2023.03.23.533944

Ejemplares similares

Mutant p53 elicits context-dependent pro-tumorigenic phenotypes
por: McCann, Jennifer J., et al.
Publicado: (2021)

PARP‐1 regulates DNA repair factor availability
por: Schiewer, Matthew J, et al.
Publicado: (2018)

Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer
por: Mandigo, Amy C., et al.
Publicado: (2022)

A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer
por: Dylgjeri, Emanuela, et al.
Publicado: (2022)

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair
por: Shafi, Ayesha A., et al.
Publicado: (2021)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials
por: Nauman, Gina, et al.
Publicado: (2018)

Advances in the use of PARP inhibitor therapy for breast cancer
por: McCann, Kelly E, et al.
Publicado: (2018)

ADP-ribosyltransferase PARP11 suppresses Zika virus in synergy with PARP12
por: Li, Lili, et al.
Publicado: (2021)

DNA-PKcs: A Targetable Protumorigenic Protein Kinase
por: Dylgjeri, Emanuela, et al.
Publicado: (2022)

(177)Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: von Eyben, Finn E., et al.
Publicado: (2021)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
por: Franza, A., et al.
Publicado: (2021)

AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy
por: Schiewer, Matthew J, et al.
Publicado: (2014)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells
por: Smith, Hannah L, et al.
Publicado: (2020)

Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line
por: Baldan, Federica, et al.
Publicado: (2015)

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)

A Review of Pomegranate in Prostate Cancer
por: Paller, Channing J., et al.
Publicado: (2017)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells
por: Morra, Francesco, et al.
Publicado: (2017)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wu, Kan, et al.
Publicado: (2021)

Timing dependent synergies between motor cortex and posterior spinal stimulation in humans
por: McIntosh, James R., et al.
Publicado: (2023)

Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial
por: Nielsen, Torben K., et al.
Publicado: (2017)

Relationship of sex steroid hormones with bone mineral density of the lumbar spine in adult men
por: Guebeli, Alissa, et al.
Publicado: (2020)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller, Channing J, et al.
Publicado: (2012)

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
por: Deek, Matthew P., et al.
Publicado: (2021)

PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
por: Marchetti, Andrea, et al.
Publicado: (2022)

Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States
por: Xu, Chenxia, et al.
Publicado: (2022)

Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
por: Nogueira Costa, Inês, et al.
Publicado: (2022)

A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer
por: Alameddine, Zakaria, et al.
Publicado: (2023)

Synergy, energy, and teamwork
por: McNamara, Sharon A.
Publicado: (2005)

Membrane Permeabilities of Ascorbic Acid and Ascorbate
por: Hannesschlaeger, Christof, et al.
Publicado: (2018)

Aurora Kinase A-YBX1 Synergy Fuels Aggressive Oncogenic Phenotypes and Chemoresistance in Castration-Resistant Prostate Cancer
por: Nikhil, Kumar, et al.
Publicado: (2020)

Increased Tumoral Microenvironmental pH Improves Cytotoxic Effect of Pharmacologic Ascorbic Acid in Castration-Resistant Prostate Cancer Cells
por: Li, Zhoulei, et al.
Publicado: (2020)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists
por: McCann, Christopher, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uv143au2epnjs4iud8g0gcfr26